Barinthus Bio

Barinthus is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates

[Barinthus Bio @BarinthusBio]

#NEWS: Today we announced encouraging early results from our Phase 1 AVALON trial of VTP-1000 for celiac disease. The completed SAD portion showed dose-dependent pharmacological effects and no treatment-related serious adverse events. Read more here: https://t.co/uFJ0HZEj3N

[Barinthus Bio @BarinthusBio]

#NEWS: Today we announced our Q3 2025 financial results. Highlights include our proposed combination with Clywedog Therapeutics, and ascending dose study data expected by the end of 2025 for VTP-1000 and in H2 2026 for the AVALON trial. Read more here: https://t.co/rNDyLXRza1

[Barinthus Bio @BarinthusBio]

Barinthus and @ClywedogTher have agreed to combine to form a stronger company that will strive to advance a promising pipeline targeting high unmet needs for metabolic and autoimmune diseases.

The combined company will be named Clywedog Therapeutics, Inc. https://t.co/HvPau5ZIL8

[Barinthus Bio @BarinthusBio]

#NEWS: Today we announced our second quarter 2025 results and corporate updates. Read the full release here: https://t.co/WZJzxpS8Fe

#BRNS #Biotech #CeliacDisease #Innovation

[Barinthus Bio @BarinthusBio]

Our CEO, Bill Enright, is speaking at the Leadership Greater Washington Summit tomorrow, diving into the potential of the biotech market and how our region can lead in the years ahead.

Learn about Barinthus: https://t.co/VUttkByMjt

#Biotech #Innovation #BRNS

[Barinthus Bio @BarinthusBio]

Next week, our Vice President of Corporate Development, Nick Fullenkamp will be attending the #BIOInternationalConvention in Boston, MA, June 16-19. We look forward to connecting with the #biotech industry.

#BarinthusBIO #BRNS #Innovation

[Barinthus Bio @BarinthusBio]

We’re attending the Q2 Virtual Investor Summit on June 10, where we will share updates on our I&I pipeline and engage with investors across the healthcare sector.

Learn more: https://t.co/6arPIGG3VR

#InvestorSummit #BRNS #Innovation #Biotech

[Barinthus Bio @BarinthusBio]

Barinthus Bio is heading to NYC for the #Jefferies2025 Global Healthcare Conference, June 3-5.

Tune in live to join our CEO, Bill Enright, for a fireside chat on June 5 at 2:35pm ET or catch the replay at https://t.co/ISu4fjsYAL.

#BRNS #Biotech #Healthcare #Innovation

[Barinthus Bio @BarinthusBio]

We will be participating in the upcoming A.G.P. Virtual Healthcare Conference this Wednesday, May 21. Looking forward to sharing our latest clinical updates and engaging with investors.

https://t.co/ISu4fjsYAL

#AGPConference #BRNS #Innovation #Immunotherapy

[Barinthus Bio @BarinthusBio]

Looking forward to presenting at the inaugural D. Boral Capital Global Conference in NYC, where we’ll share updates and connect with investors about our I&I pipeline.

#DBCConference #BRNS #Biotech #Immunotherapy

[Barinthus Bio @BarinthusBio]

Today we announced our Q1 financial results and provided updates on our strategic focus on I&I diseases, our highly differentiated lead asset for celiac disease with data due Q3 25, proprietary SNAP-TI platform and cash runway into 2027. Read more: https://t.co/jfpX29eW8v

[Barinthus Bio @BarinthusBio]

Great to have two poster presentations, LBP-004 & LBP-020, at the 2025 EASL Congress where Barinthus will showcase its latest clinical results for its investigational asset designated for partnering in chronic hepatitis B.

#EASLCongress #BRNS #Immunotherapy #Partnership

[Barinthus Bio @BarinthusBio]

Today we announced our FY 2024 financial results and provided updates on our strategic focus on I&I diseases, VTP-1000, a potentially curative immunotherapy for celiac disease with data due H2 25, proprietary SNAP-TI platform & extended cash runway: https://t.co/h8ggFRTA8R

[Barinthus Bio @BarinthusBio]

#NEWS: We named Geoffrey Lynn, M.D., Ph.D. as our Chief Scientific Officer. Dr. Lynn has more than 15 years of experience leading immunotherapeutic R&D from discovery through early development. Read the full release: https://t.co/ZgdGAL9Ydk
$BRNS #immunotherapy

[Barinthus Bio @BarinthusBio]

Our VP of Research, Sarah Sebastian, will be presenting at the British Society for Immunology Immune Therapies Summit on Monday 25 November, talking about antigen-specific tolerance induction via our proprietary SNAP-TI platform. Read more here: https://t.co/9TDnXNLHQH
$BRNS

[Barinthus Bio @BarinthusBio]

#NEWS: Today we shared positive results from two ongoing chronic hepatitis b #clinicaltrials, including patients who met the criteria for functional cure. We will be presenting data at AASLD - The Liver Meeting®. Read more: https://t.co/2JLAJuKlIm
#TLM24 $BRNS

[Barinthus Bio @BarinthusBio]

#Investors and #partners: Meet with us at @jefferies London Healthcare Conference starting November 19. We’ll have our latest #hepatitisB data from AASLD and will be available for one-on-one meetings. Learn more: https://t.co/rEnIFSOLxg $BRNS #jefferieshealthcare

[Barinthus Bio @BarinthusBio]

We’re at @GuggenheimPtnrs Healthcare Talks Conference today. Watch our CEO @benrights fireside chat at 14:00 ET to get the latest update on Barinthus Bio’s innovative technologies. Watch it here: https://t.co/vlMcTPUoLK

$BRNS

[Barinthus Bio @BarinthusBio]

The countdown to AASLD - The Liver Meeting® is on! We’ll be presenting updated data from our #clinicaltrials in #hepatitis B. Learn more about our viral vector platform: https://t.co/xpqlE9YAVx

#TLM24 $BRNS

[Barinthus Bio @BarinthusBio]

Today we announced our third quarter 2024 financial results and provided an overview of our business updates.
The latest news is available here: https://t.co/TW0vDrGUPx
#Biotech #Immunotherapy #Finance $BRNS